News

Neurotech Reports, the publisher of this newsletter, announced that the fourth annual Neurotech Commercialization Workshop will take place on July 27, 2023. The one-day event will take place on-line using the Zoom platform. The workshop will feature tutorial and interactive sessions with Neurotech Reports editors James Cavuoto, Jeremy Koff, and Jo Jo Platt. The morning agenda, free to advanced regi…

In the evolving landscape of medical advancements, an emerging field of interest is the use of ultrasound technology for therapeutic neuromodulation. The application of ultrasound to modulate the function of peripheral nerve pathways is called peripheral focused ultrasound stimulation and is becoming a potential tool in the management of chronic diseases. A recent study by a team at GE Research, di…

The National Institutes of Health held the 9th Annual BRAIN Initiative Meeting in Bethesda, MD earlier this month. The hybrid meeting was the first to welcome in-person attendance since before the pandemic. Eager researchers and enthusiasts alike grabbed the limited number of spots for in person attendance causing the organizers to put people on a waiting list while they arranged for additional space at the meeting site.

Long-time readers of this publication will recall that we have frequently approached the subjects of ethics in neurotechnology and protecting users’ privacy. Particularly in this space, we have long advocated for “neuro vigilance” against potential threats posed -computer interfaces and deep-brain stimulation. And as NBR senior contributing editor JoJo Platt points out in her coverage of the recent…

Glioblastoma, the deadly brain cancer that impacts about 12,000 people in the U.S. each year, remains one of the most significant unmet medical needs facing the healthcare industry. The five-year survival rate is under 10% and patients survive an average of 15 to 18 months after diagnosis. Recently, several emerging bioelectronic medicine firms and research teams have reported progress at developing therapies for glioblastoma, though there is still a long road ahead for these efforts.

One of the greatest challenges confronting pain clinicians and healthcare firms targeting chronic pain has been the lack of an objective measure of pain intensity. Although subjective tests such as the VAS score are available to patients and pain doctors, there could be wide variability in the perceived level of pain among different subjects and at different times. This situation not only makes it…

About 80 professionals from the Bioelectronic Medicine industry attended the sixth annual Bioelectronic Medicine Forum, held in New York City earlier this month. The event, produced , was held at the New York Academy of Medicine in Manhattan, with some participants joining via Zoom. The full-day conference featured several panel discussions on topics related to bioelectronic medicine, as well as presentations from 10 startup firms in the space.

proved to be a busy month for the neurotechnology industry, as evidenced of Neurotech Business Report . If one theme stands out among the several groundbreaking studies and commercial developments this month, it is the importance of developing personalized therapies that are tailored to each patient. As we report in our coverage of the American Psychiatric Association meeting in San Francisco [see…

The global cardiac rhythm management industry, or more generally the field of cardiac bioelectronic implantable devices (CBID), offers an interesting showcase for examining the field of bioelectronic medicine. The evolution of the cardiac device industry can provide insights regarding dynamics that drove growth and altered competitive landscapes. If we examine this market and some of its inflection points this can inform us about opportunities and challenges faced today within bioelectronic medicine.

The market for spinal cord stimulation systems got a little more crowded this month when Biotronik, the German medtech manufacturer, announced FDA approval for its Prospera system. Biotronik is a major player in the cardiac devices market, where it competes with Medtronic, Boston Scientific, and Abbott—three incumbents in the SCS space. The company launched a new business segment called Biotronik Neuro, based in Lake Oswego, OR, to pursue the neuromodulation market.